The Designed for intravenous (IV) Ibandronate reNal safety Evaluation (DIVINE) study was a 1-year prospective, randomized, open label, multi-center study that evaluated the renal safety of quarterly (every 3 months) ibandronate IV injection given over 15-30s compared with infusion given over 15 min, and weekly oral alendronate, in women with postmenopausal osteoporosis (PMO) at increased risk f...

PURPOSE A mixed-treatment comparison (MTC) was undertaken to compare the efficacy of zoledronic acid, clodronate, pamidronate, and ibandronate (i.v. and oral) in patients with skeletal-related events (SRE) secondary to metastatic breast and prostate cancer and multiple myeloma. EXPERIMENTAL DESIGN Studies of bisphosphonates in the three malignancies were identified and SRE data were extracted...

Renal safety is an important consideration for oncologists who are treating patients with bisphosphonates. In recent years, there has been increasing awareness about the development of bisphosphonate-induced nephrotoxicity. This has emerged mainly from increased clinical experience with zoledronic acid (Zometa); Novartis Pharmaceuticals Corporation, East Hanover, NJ, http://www.pharma.us.novart...

Let IBn be the set of all irreducible matrices in Bn and let SIBn be the set of all symmetric matrices in IBn. Finding an upper bound for the set of indices of matrices in IBn and SIBn and determining gaps in the set of indices of matrices in IBn and SIBn has been studied by many researchers. In this paper, we establish a best upper bound for the set of weak exponents of indecomposability of ma...

CONTEXT Ibandronate, a potent, nitrogen-containing bisphosphonate developed for intermittent administration in postmenopausal osteoporosis, aims to overcome current adherence issues with daily and weekly oral bisphosphonates through once-monthly oral dosing. OBJECTIVE The purpose of this study was to investigate the safety, pharmacodynamics, and pharmacokinetics of once-monthly oral ibandrona...

BACKGROUND Aim of the present study was to identify the predictors of ibandronate efficacy in subjects with osteoporosis or decreased bone mineral density (BMD). METHOD Several electronic databases were searched by using specific keywords for the acquisition of research articles reporting the efficacy of ibandronate in subjects with osteoporosis or decreased BMD. Metaregression analyses were ...

The Oncologist 2005;10:313–314 www.TheOncologist.com The recent article by Conte and Guarneri highlights numerous safety and compliance issues of intravenous and oral bisphosphonates in patients with metastatic bone disease [1]. I believe it is essential that readers of The Oncologist are made aware of a few of the inaccuracies within the article, particularly those renal safety statements that...

In this work we consider the design principles of the Instance-Based Network (IBN), an extended version of a generic Content-Based Network(CBN). IBN acts as an overlay communication platform over which end-point entities, called contents, communicate independently from their physical locations while providing the flexibility of having different instances of the same content. The semantics of di...

Despite their efficacy in treating complications associated with metastatic bone disease, there are concerns about the potential nephrotoxicity of certain i.v. bisphosphonates for the long-term management of cancer patients. Clinical data suggest, however, that i.v. ibandronate (Bondronat); F. Hoffman-La Roche Ltd., Basel, Switzerland, http://www.roche.com), unlike other bisphosphonates, has a ...

The purpose of this study was to perform a meta-analysis on the efficacy of ibandronate by evaluating the effect sizes of different dosing regimens.Major electronic databases were searched from 1985 to February 2015. A random effects meta-analysis was performed in STATA.Data from 34 studies (13,639 patients) were included in this meta-analysis. Ibandronate treatment significantly improved lumba...